Hepatitis C cure rates with ledipasvir/sofosbuvir (Harvoni) proved nearly identical in patients treated by hepatitis specialists, by primary care providers or by nurse practitioners.
Hepatitis C cure rates using elbasvir/grazoprevir (Zepatier) was 93% in individuals with genotypes 1 or 4, in a study of patients in Asia and Russia.
Cirrhotic hepatitis-C patients in Denmark had a 63% lower risk of liver cancer and a 76% lower risk of decompensated cirrhosis if they achieved a cure with direct-acting antivirals.
Despite the diversity of new direct-acting antivirals (DAAs), a tiny number of patients are still left behind. Nancy Reau, M.D., presented a summary of soon-to-be-approved drugs that should work for these tough-to-treat patients.
Prevalence of cardiovascular disease, renal impairment and fractures or osteoporosis was higher with than without HIV every year from 2003 to 2013.
State Medicaid Programs Ease Illegal Restrictions on Hepatitis C Medications, but More Progress Needed
While restrictions for obtaining hepatitis C drugs through Medicaid programs vary state by state, restrictions eased somewhat across the country from 2014 to 2016, according to data presented at the Liver Meeting 2016.
Switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) improved kidney and bone markers in a study focused on people 50 years old or older.
Individuals living with hepatitis C and cirrhosis who are treated with direct-acting antivirals do not face a higher risk of developing liver cancer when compared with untreated individuals, according to a study presented at the Liver Meeting 2016....
Antiretroviral therapy reduced systemic and central nervous system (CNS) inflammation in past substance users compared with nonusers, according to the results of a study presented at IDWeek 2016.
Anal cancer screening was uncommon -- at only 11% -- among a study of HIV-positive men who have sex with men (MSM) receiving HIV care, despite this community being at a significantly higher risk for anal cancer, according to a study presented at IDWe...